Literature DB >> 12498507

A utility analysis correlation with visual acuity: methodologies and vision in the better and poorer eyes.

M M Brown1, G C Brown, S Sharma, A F Smith, J Landy.   

Abstract

OBJECTIVE: To ascertain the correlation between visual acuity levels and ophthalmic utility values obtained using time tradeoff and standard gamble utility analysis methodologies.
METHODS: Three hundred twenty-five consecutive patients with visual loss to 20/40 or less in at least one eye with predominantly vitreoretinal pathology were evaluated in a cross-sectional fashion using a standardized testing methodology to obtain ophthalmic time tradeoff and standard gamble utility values. Spearman correlation coefficients were employed to correlate the utility values with visual acuity in better seeing and poorer seeing eyes.
RESULTS: The Spearman correlation coefficient for time tradeoff utility values and vision in the better seeing eye was 0.455 (p < 0.001), while that for time tradeoff utility values and visual acuity in the poorer seeing eye was 0.268 (p < 0.001). The coefficient for standard gamble utility values and the better seeing eye was 0.371 (p < 0.001), while that for standard gamble utility values and vision in the poorer seeing eye was 0.250 (p < 0.001).
CONCLUSIONS: There is a greater correlation between ophthalmic utility values and vision in the better seeing eye, as versus vision in the poorer seeing eye. Time tradeoff ophthalmic utility values demonstrate a greater correlation with vision in the better seeing eye than do standard gamble utility values.

Entities:  

Mesh:

Year:  2001        PMID: 12498507     DOI: 10.1023/a:1021171000838

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  28 in total

1.  Health care in the 21st century: evidence-based medicine, patient preference-based quality, and cost effectiveness.

Authors:  G C Brown; M M Brown; S Sharma
Journal:  Qual Manag Health Care       Date:  2000       Impact factor: 0.926

Review 2.  Quality and cost effectiveness in health care: a unique approach.

Authors:  G C Brown; M M Brown; S Sharma
Journal:  J Ophthalmic Nurs Technol       Date:  2000 Jan-Feb

3.  Utility values and age-related macular degeneration.

Authors:  G C Brown; S Sharma; M M Brown; J Kistler
Journal:  Arch Ophthalmol       Date:  2000-01

4.  Scaling of visual acuity measurements.

Authors:  G Westheimer
Journal:  Arch Ophthalmol       Date:  1979-02

5.  Preference values for visual states in patients planning to undergo cataract surgery.

Authors:  E B Bass; S Wills; I U Scott; J C Javitt; J M Tielsch; O D Schein; E P Steinberg
Journal:  Med Decis Making       Date:  1997 Jul-Sep       Impact factor: 2.583

6.  Explaining distortions in utility elicitation through the rank-dependent model for risky choices.

Authors:  P Wakker; A Stiggelbout
Journal:  Med Decis Making       Date:  1995 Apr-Jun       Impact factor: 2.583

7.  Visual acuity: calculating appropriate averages.

Authors:  M J Moseley; H S Jones
Journal:  Acta Ophthalmol (Copenh)       Date:  1993-06

8.  Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization.

Authors:  G C Brown; M M Brown; S Sharma; H Brown; W Tasman
Journal:  Ophthalmology       Date:  2000-07       Impact factor: 12.079

9.  The VF-14. An index of functional impairment in patients with cataract.

Authors:  E P Steinberg; J M Tielsch; O D Schein; J C Javitt; P Sharkey; S D Cassard; M W Legro; M Diener-West; E B Bass; A M Damiano
Journal:  Arch Ophthalmol       Date:  1994-05

Review 10.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

View more
  9 in total

1.  Quality of life and relative importance: a comparison of time trade-off and conjoint analysis methods in patients with age-related macular degeneration.

Authors:  P A Aspinall; A R Hill; B Dhillon; A M Armbrecht; P Nelson; C Lumsden; E Farini-Hudson; R Brice; A Vickers; P Buchholz
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

2.  The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.

Authors:  Gary C Brown; Melissa M Brown; Heidi C Brown; Sylvia Kindermann; Sanjay Sharma
Journal:  Trans Am Ophthalmol Soc       Date:  2007

3.  The impact of persistent visually disabling vitreous floaters on health status utility values.

Authors:  Haidong Zou; Haiyun Liu; Xun Xu; Xi Zhang
Journal:  Qual Life Res       Date:  2012-10-11       Impact factor: 4.147

Review 4.  [Value-based medicine for glaucoma].

Authors:  C Hirneiss; A Kampik; A S Neubauer
Journal:  Ophthalmologe       Date:  2010-03       Impact factor: 1.059

5.  The clinical features and the factors affecting visual prognosis in pediatric open-globe ınjuries.

Authors:  Hakan Öztürk; Bediz Özen
Journal:  Int Ophthalmol       Date:  2022-05-17       Impact factor: 2.029

6.  Quality-adjusted life years in macular oedema due to age-related macular degeneration, diabetes and central retinal vein occlusion: the impact of anti-VEGF agents in a tertiary centre in Greece.

Authors:  Nikolaos T Voutsas; Eleni Papageorgiou; Alexandra Tantou; Vassilis A Dimitriou; Evangelia E Tsironi; Maria Kotoula
Journal:  Int Ophthalmol       Date:  2022-04-13       Impact factor: 2.029

Review 7.  The value of vision.

Authors:  Christine Knauer; Norbert Pfeiffer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-12-11       Impact factor: 3.117

8.  Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study.

Authors:  Winfried M Amoaku; Richard P Gale; Andrew J Lotery; Geeta Menon; Sobha Sivaprasad; Jennifer Petrillo; Jennifer Quinn
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

Review 9.  Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review.

Authors:  Edith Poku; John Brazier; Jill Carlton; Alberto Ferreira
Journal:  BMC Ophthalmol       Date:  2013-12-04       Impact factor: 2.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.